Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T13:31:11.137Z.
Calculation as of: 2026-10-06T13:31:11.137Z.
Quote observation: 2026-10-06T13:30:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ae4e4394aaeb0d5c8b7c6b49623c27b4c6984d6a5511a37bd4b8ffeab1df45fa
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Curanex Pharmaceuticals Inc Common Stock
Market Cap
$7.21M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.85M
EV/EBITDA Ratio
N/A
TTM Avg
34.26x
3Y Avg
34.26x
5Y Avg
668.76x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Curanex Pharmaceuticals Inc Common Stock (CURX) | $7.21M | N/A | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $7.00M | N/A | 1.39x | 7.68x | 7.68x |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.85M | N/A | 34.26x | 34.26x | 668.76x |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.58M | N/A | N/A | N/A | N/A |
| Longeveron Inc. (LGVN)vs › | $7.61M | N/A | N/A | N/A | N/A |
| Aclarion, Inc. (ACON)vs › | $6.80M | N/A | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $6.77M | N/A | N/A | N/A | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.72M | N/A | N/A | N/A | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.89M | N/A | N/A | N/A | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $7.96M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
